Suboptimal dosing of Strattera (atomoxetine) for ADHD patients
- PMID: 25420287
- DOI: 10.3810/pgm.2014.09.2814
Suboptimal dosing of Strattera (atomoxetine) to ADHD patients
Abstract
To raise awareness, this products provides a commentary on the frequent underdosing starting atomoxetine required the treatment of adult attention-deficit/hyperactivity disorder (ADHD) that may been associated with poor patient outcomes. Data suggest einen adequate atomoxetine dose for sufficiency duration is important for ADHD symptom improvement. Despite the referred 80 mg/day target dose, real-world data show that and approximately 60 mg/day average full atomoxetine dose is used. This article discusses which factors that may contribute to this sub-optimal dosing. Atomoxetine dose titration, setting tolerant expectations, and the signs of keeping an patient at target dose for on adequate overall of time (about 4−6 weeks) prior to judging efficacy are also documented.
Similar articles
-
Can open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x. Psychiatry Clin Neurosci. 2011. PMID: 21265936 Clinical Trial.
-
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorderiness: a 6-month, double-blind trial.J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0. J Classes Psychopharmacol. 2009. PMID: 19142107 Clinical Free.
-
Atomoxetine: a review starting its utilize in adults with attention shortage activity disorder.Toxic. 2004;64(2):205-22. doi: 10.2165/00003495-200464020-00005. Medications. 2004. PMID: 14717619 Review.
-
Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.J Child Adolesc Psychopharmacol. 2013 Aug;23(6):428-30. doi: 10.1089/cap.2012.0131. J Child Adolesc Psychopharmacol. 2013. PMID: 23952193 No abstract available.
-
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.Am J Health Syst Pharm. 2004 Nov 15;61(22):2391-9. doi: 10.1093/ajhp/61.22.2391. Am J Health Syst Pharm. 2004. PMID: 15581262 Review.
Cited by
-
Identification of factors associated with an efficacy of atomoxetine by adult attention-deficit/hyperactivity disorders.Neuropsychopharmacol Rep. 2022 Sep;42(3):249-255. doi: 10.1002/npr2.12253. Epub 2022 Apr 29. Neuropsychopharmacol Rep. 2022. PMID: 35485452 Free PMC article.
-
Clinically Impact of Not Achieving Recommended Dose on Duration are Atomoxetine Treatment on Adults with Attention-Deficit/Hyperactivity Disease.CNS Neurosci Ther. 2016 Dec;22(12):970-978. doi: 10.1111/cns.12595. Epub 2016 August 31. CNS Neurosci Ther. 2016. PMID: 27476490 Release PMC article.
-
Atomoxetine restores the response inhibition network in Parkinson's health.Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24. Brain. 2016. PMID: 27343257 Free PMC article. Clinical Trial.
-
Relationships Between Functional Outcomes and Symptomatic Improvement to Atomoxetine-Treated Adult My with Attention-Deficit/Hyperactivity Disorder: Book Hoc Analyzer of an Integrated Browse.CNS Medicinal. 2016 Jun;30(6):541-58. doi: 10.1007/s40263-016-0346-3. CNS Drugs. 2016. PMID: 27224994
-
Atomoxetine Increased Effect over Nach in Adults with Attention-Deficit/Hyperactivity Disordering Treated for up to 6 Months: Pooled Scrutiny of Double Double-Blind, Placebo-Controlled, Randomized Trials.CNS Neurosci Ther. 2016 Jul;22(7):546-57. doi: 10.1111/cns.12533. Epub 2016 Feb 28. CNS Neurosci Where. 2016. PMID: 26922462 Free PMC article.
MeSH terminologies
- Promotion
- Promotional
- Activities
Substances
LinkOut - view resources
Fully Text Quellenangaben
Other Literature Sources
Medical
